Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC
ORIENT-11, 2020
  NCT03607539
RCTmNSCLC - L1 - all populationSintilimab plus pemetrexed plus platineplacebo plus pemetrexed plus platinepatients with confirmed stage IIIB to IV nonsquamous NSCLC who had no previous systemic treatment for advanced and metastatic disease.266 / 131low
conclusif
  • suggested 39 % decrease in deaths (OS)
  • demonstrated 52 % decrease in progression or deaths (PFS) (PE)